Acute and subacute antidiabetic studies of ENP‐9, a new 1,5‐diarylpyrazole derivative

Objectives To explore the antihyperglycaemic and antidiabetic effects and to determine the acute toxicity of 5‐(4‐chlorophenyl)‐1‐(2,4‐dichloro‐phenyl)‐4‐methyl‐N‐(piperidin‐1‐yl)‐1H‐pyrazole‐3‐carboxamide (ENP‐9). Methods The antihyperglycaemic effect of ENP‐9 (50 mg/kg) was determined by oral glucose tolerance test (OGTT). Also, the acute (16, 50 and 160 mg/kg) and subacute (50 mg/kg/day for 10 days) antidiabetic effects of ENP‐9 were determined. After subacute treatment, blood samples were analysed to determine glucose and lipid profiles. Also, an acute toxicity determination of ENP‐9 was conducted followed the OECD recommendation. Molecular docking was performed using AutoDock 4.2.6 at human cannabinoid receptor 1 (PDB code 5TGZ). Key findings Acute Administration of ENP‐9 showed significant antidiabetic effect and decreased the maximum OGTT peak, compared to the control group (P